#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring

Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday. The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse ...